Article

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab

2021-04-07

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Tocilizumab (TCZ) is an interleukin-6 inhibitor and the second established effective drug for the treatment of hospitalized patients with Covid-19. In this study, we sought to validate the recent positive findings from the randomised clinical trial RECOVERY and to evaluate the challenges in the analysis and interpretation of non-randomized comparative effectiveness studies in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9cfe03ff-e21c-5ce0-a3b5-1a60dd308ea9
DOI: 10.1101/2021.04.06.21254612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumabDOI 10.1101/2021.04.06.21254612Read

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and ScotlandSemantic proximity Read

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read

Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic reviewSemantic proximity Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

Single Versus Multiple Doses of Tocilizumab in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Two-center, Retrospective Cohort StudySemantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.Semantic proximity Read

Challenges and Lessons Learned from COVID-19 Trials – Should We be Doing Clinical Trials Differently?Semantic proximity Read

How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.govSemantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational studySemantic proximity Read

A snapshot of the ongoing clinical research on COVID-19Semantic proximity Read